Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19,154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study.
Lev-Ari S, Serzan M, Wu T, Ip A, Pascual L, Sinclaire B, Adams S, Marafelias M, Ayyagari L, Gill SK, Ma B, Zaemes JP, Della Pia A, Alaoui A, Madhavan S, Belouali A, Pecora A, Ahn J, Atkins MB, Shah NJ. Lev-Ari S, et al. Among authors: wu t. Cancer. 2023 Jun 15;129(12):1885-1894. doi: 10.1002/cncr.34742. Epub 2023 Mar 23. Cancer. 2023. PMID: 36951119
Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer.
Lynce F, Blackburn MJ, Zhuo R, Gallagher C, Hahn OM, Abu-Khalaf M, Mohebtash M, Wu T, Pohlmann PR, Dilawari A, Tiwari SR, Chitalia A, Warren R, Tan M, Shajahan-Haq AN, Isaacs C. Lynce F, et al. Among authors: wu t. Cancer. 2021 Oct 1;127(19):3622-3630. doi: 10.1002/cncr.33620. Epub 2021 Jun 22. Cancer. 2021. PMID: 34157782 Free article. Clinical Trial.
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
Pohlmann PR, Graham D, Wu T, Ottaviano Y, Mohebtash M, Kurian S, McNamara D, Lynce F, Warren R, Dilawari A, Rao S, Mainor C, Swanson N, Tan M, Isaacs C, Swain SM. Pohlmann PR, et al. Among authors: wu t. Breast Cancer Res Treat. 2022 Dec;196(3):571-581. doi: 10.1007/s10549-022-06743-9. Epub 2022 Oct 25. Breast Cancer Res Treat. 2022. PMID: 36280642 Free PMC article. Clinical Trial.
Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
Coutts SB, Ankolekar S, Appireddy R, Arenillas JF, Assis Z, Bailey P, Barber PA, Bazan R, Buck BH, Butcher KS, Camden MC, Campbell B, Casaubon LK, Catanese L, Chatterjee K, Choi PMC, Clarke B, Dowlatshahi D, Ferrari J, Field TS, Ganesh A, Ghia D, Goyal M, Greisenegger S, Halse O, Horn M, Hunter G, Imoukhuede O, Kelly PJ, Kennedy J, Kenney C, Kleinig TJ, Krishnan K, Lima F, Mandzia JL, Marko M, Martins SO, Medvedev G, Menon BK, Mishra SM, Molina C, Moussaddy A, Muir KW, Parsons MW, Penn AMW, Pille A, Pontes-Neto OM, Roffe C, Serena J, Simister R, Singh N, Spratt N, Strbian D, Tham CH, Wiggam MI, Williams DJ, Willmot MR, Wu T, Yu AYX, Zachariah G, Zafar A, Zerna C, Hill MD; TEMPO-2 investigators. Coutts SB, et al. Among authors: wu t. Lancet. 2024 May 16:S0140-6736(24)00921-8. doi: 10.1016/S0140-6736(24)00921-8. Online ahead of print. Lancet. 2024. PMID: 38768626
Hepatocellular carcinoma: Advances in systemic therapies.
Wu TK, Hui RW, Mak LY, Fung J, Seto WK, Yuen MF. Wu TK, et al. F1000Res. 2024 May 7;13:104. doi: 10.12688/f1000research.145493.2. eCollection 2024. F1000Res. 2024. PMID: 38766497 Free PMC article. Review.
19,154 results
You have reached the last available page of results. Please see the User Guide for more information.